Major Isolates Distribution and the Drug Resistance Changes of Multidrug-resistant Organism in 2013_West China Medical Journal

Authors：

 WangHuiling , LuXianlei

Department of Nosocomial Infection, the Fifth People's Hospital of Chengdu, Chengdu, Sichuan 611130, P. R. China;

Corresponding?author：

Keywords：

Nosocomial infection; Drug resistance surveillance; Antibiotics

DOI：

10.7507/1002-0179.20160077

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To find out the major isolates distribution, drug resistance changes of multidrug-resistant organisms (MDRO) in 2013 for rational use of antibiotics and hospital infection control. Methods A total of 32 566 cultured bacteria samples from the patients diagnosed between January 1st and December 31st 2013 were collected, using conventional tube biochemical assays and semi-automatic automicrobic (AMS) for bacteria identification; and antimicrobial susceptibility testing, major drug resistance mechanism detection were performed according to CLSI documents. MDRO definition was made according to the 2011 international consensus from European Center for Disease Control and Prevention (CDC), American CDC, Clinical and Laboratory Standards Institute (CLSI), and Food and Drug Administration. The data was analyzed by WHOnet 5.6 software. Results We got 3 684 strains isolates, G^- accounted for 76.08%, G⁺ 16.80%, fungi 7.11%, and fastidious bacteria 17.29%. The top ten isolates in order were:E.coli, A.baumannii, Ps.aeruginosa, H.influenzae, K.pneumoniae, S.aureus, S.pneumoniae, A.fumigatus, M.catarrhalis and C.freundii. From the first quarter 2012 to the fourth quarter 2013, the extended spectrum β lactamases (ESBL)-producing E.coli increased from 40.23% to 53.54%, ESBL-producing K.pneumonia increased from 14.28% to 34.78%, XDR-A.baumannii increased from 62.38% to 99.25%, metalloenzyme-producing Ps.aeruginosa increased from 7.37% to 25.37%, methicillin resistant staphylococcus aureus increased from 23.81% to 58.70%, and VRE increased from 0.00% to 28.12%. Conclusion In the isolates, the percentage of G^- was the highest, and the rate of MDRO are all unremittingly raising, which suggests us should pay more attention to microbiology analysis, rational use of antibiotics, strengthening hospital infection control, reducing the bacterial resistance, and strengthening MDRO surveillance.

Citation： WangHuiling, LuXianlei. Major Isolates Distribution and the Drug Resistance Changes of Multidrug-resistant Organism in 2013. West China Medical Journal, 2016, 31(2): 287-292. doi: 10.7507/1002-0179.20160077 Copy

1.	李耘, 呂媛, 薛峰, 等. 衛生部全國細菌耐藥監測網(Mohnarin) 2011-2012年革蘭陽性菌耐藥監測報告[J]. 中國臨床藥理學雜志, 2014, 30(3):251-259.
2.	胡付品, 朱德妹, 汪復, 等. 2013年中國CHINET細菌耐藥性監測[J]. 中國感染與化療雜志, 2014, 14(5):365-374.
3.	Versalovic J, Carroll KC, Pfaller MA, et al. Manual of clinical microbiology[M]. 10th ed. Washington, D.C:American Society for Microbiology, 2011.
4.	陳東科, 孫長貴. 實用臨床微生物檢驗與圖譜[M]. 北京:人民衛生出版社, 2011.
5.	王端禮, 李若瑜, 王愛平. 醫學真菌學——實驗室檢驗指南[M]. 北京:人民衛生出版社, 2005.
6.	中華檢驗醫學雜志CLSI臨床檢驗標準編譯小組. 抗菌藥物敏感性試驗執行標準;第二十三版資料增刊[J]. 中華檢驗醫學雜志, 2013, 33(1):M100-S23.
7.	李春輝, 吳安華. 醫療機構耐藥菌MDR、XDR、PDR的國際標準化定義專家建議(草案)[J]. 中國感染控制雜志, 2011, 10(3):238-240.
8.	李多, 李光榮, 向成玉. 2008年臨床分離病原菌分布及耐藥性分析[J]. 中華醫院感染學雜志, 2010, 20(8):1155-1158.
9.	林昌鋒, 邢貽雄, 陳如壽. 綜合性醫院病原菌分布及耐藥性分析[J]. 中華醫院感染學雜志, 2009, 19(3):335-337.
10.	郭慶芳, 楊春艷. 我院2007-2008年細菌耐藥性監測與分析[J]. 中國醫院藥學雜志, 2010, 30(16):1407-1410.
11.	李玉瑭, 于超, 杜亭亭, 等. 2010年醫院臨床分離細菌的耐藥性監測[J]. 中華醫院感染學雜志, 2012, 22(19):4379-4381.
12.	Simner PJ, Zhanel GG, Pitout J, et al. Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli:results of the CANWARD 2007-2009 study[J]. Diagn Microbiol Infect Dis, 2011, 69(3):326-334.
13.	張立平, 鄧麗, 鄭麗華, 等. 2007-2009年臨床病原菌分布及耐藥趨勢分析[J]. 中華醫院感染學雜志, 2011, 21(6):1220-1223.
14.	王衛華, 陳潔, 李春仙, 等. 泛耐藥鮑氏不動桿菌β-內酰胺酶、膜孔蛋白、外排泵編碼基因研究[J]. 中華醫院感染學雜志, 2012, 22(10):2001-2004.
15.	Jilu Shen YP, Fang YP. Role of the outer membrane protein OprD2 in carbapenem-resistance mechanisms of Pseudomonas aeruginosa[J]. PLoS One, 2015, 10(10):e0139995.

1. 李耘, 呂媛, 薛峰, 等. 衛生部全國細菌耐藥監測網(Mohnarin) 2011-2012年革蘭陽性菌耐藥監測報告[J]. 中國臨床藥理學雜志, 2014, 30(3):251-259.
2. 胡付品, 朱德妹, 汪復, 等. 2013年中國CHINET細菌耐藥性監測[J]. 中國感染與化療雜志, 2014, 14(5):365-374.
3. Versalovic J, Carroll KC, Pfaller MA, et al. Manual of clinical microbiology[M]. 10th ed. Washington, D.C:American Society for Microbiology, 2011.
4. 陳東科, 孫長貴. 實用臨床微生物檢驗與圖譜[M]. 北京:人民衛生出版社, 2011.
5. 王端禮, 李若瑜, 王愛平. 醫學真菌學——實驗室檢驗指南[M]. 北京:人民衛生出版社, 2005.
6. 中華檢驗醫學雜志CLSI臨床檢驗標準編譯小組. 抗菌藥物敏感性試驗執行標準;第二十三版資料增刊[J]. 中華檢驗醫學雜志, 2013, 33(1):M100-S23.
7. 李春輝, 吳安華. 醫療機構耐藥菌MDR、XDR、PDR的國際標準化定義專家建議(草案)[J]. 中國感染控制雜志, 2011, 10(3):238-240.
8. 李多, 李光榮, 向成玉. 2008年臨床分離病原菌分布及耐藥性分析[J]. 中華醫院感染學雜志, 2010, 20(8):1155-1158.
9. 林昌鋒, 邢貽雄, 陳如壽. 綜合性醫院病原菌分布及耐藥性分析[J]. 中華醫院感染學雜志, 2009, 19(3):335-337.
10. 郭慶芳, 楊春艷. 我院2007-2008年細菌耐藥性監測與分析[J]. 中國醫院藥學雜志, 2010, 30(16):1407-1410.
11. 李玉瑭, 于超, 杜亭亭, 等. 2010年醫院臨床分離細菌的耐藥性監測[J]. 中華醫院感染學雜志, 2012, 22(19):4379-4381.
12. Simner PJ, Zhanel GG, Pitout J, et al. Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli:results of the CANWARD 2007-2009 study[J]. Diagn Microbiol Infect Dis, 2011, 69(3):326-334.
13. 張立平, 鄧麗, 鄭麗華, 等. 2007-2009年臨床病原菌分布及耐藥趨勢分析[J]. 中華醫院感染學雜志, 2011, 21(6):1220-1223.
14. 王衛華, 陳潔, 李春仙, 等. 泛耐藥鮑氏不動桿菌β-內酰胺酶、膜孔蛋白、外排泵編碼基因研究[J]. 中華醫院感染學雜志, 2012, 22(10):2001-2004.
15. Jilu Shen YP, Fang YP. Role of the outer membrane protein OprD2 in carbapenem-resistance mechanisms of Pseudomonas aeruginosa[J]. PLoS One, 2015, 10(10):e0139995.

Previous Article
Effects of Pilose Antler Blood Wine on Bone Mineral Density and T-lymphocyte Subsets in Ovariectomized Female Rats
Next Article
Study on the CT Features of Coronary Artery Aneurysm

West China Medical Journal

Major Isolates Distribution and the Drug Resistance Changes of Multidrug-resistant Organism in 2013

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content